ARTICLE | Clinical News
Pharmacyclics Phase III continues
January 9, 2001 8:00 AM UTC
PCYC enrolled 390 of 425 patients in its international Phase III trial of Xcytrin motexafin gadolinium, an injectable radiosensitizer to treat cancer metastasized to the brain. The company said its in...